.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

TRK Inhibitors in Lung and GI Cancers

EP. 1: Role of NTRK Inhibitors

May 21st 2020

EP. 2: Variants of NTRK Fusions in Solid Tumors

May 21st 2020

EP. 3: Evolution of NGS Testing in Lung Cancers

May 21st 2020

EP. 4: Using Molecular Testing in GI Cancers

May 21st 2020

EP. 5: Approaching Genomic Testing for NTRK Fusions

May 21st 2020

EP. 6: Genomic Testing for NTRK Fusions in Lung and GI Cancers

May 21st 2020

EP. 7: Driver Mutations in NTRK Fusion-Positive Cancers

May 21st 2020

EP. 8: Advice for Interpreting NGS Reports

May 21st 2020

EP. 9: Early Development of TRK Inhibitors

May 21st 2020

EP. 10: Efficacy of TRK Inhibitors

May 21st 2020

EP. 11: TRK Inhibitor in GI Cancers: Adverse Effect Profile

May 21st 2020

EP. 12: Approaching Treatment for TRK Fusion–Positive Cancers

May 21st 2020

EP. 13: Acquired Resistance in TRK Fusion-Positive Cancers

May 21st 2020

EP. 14: Challenges for TRK Fusion–Targeting Agents

May 21st 2020

EP. 15: Future of NTRK Fusions

May 21st 2020